EVENT

16th Annual Personalized Medicine Conference

KPMG at the 16th Annual Personalized Medicine Conference

Ritz-Carlton Laguna Niguel | Dana Point, CA

Ash Shehata

Ash Shehata

Principal, National Sector Leader for HCLS, KPMG US

+1 513-763-2428

Steve Sapletal

Steve Sapletal

Principal, National Life Sciences Advisory Leader, KPMG US

+1 612-708-2556

Kristin C. Pothier

Kristin C. Pothier

Global and National Leader, HCLS Strategy, KPMG LLP

+1 617 549 2779

Alasdair Milton, PhD

Alasdair Milton, PhD

Managing Director, Healthcare and Life Sciences Strategy, KPMG US

+1 617-988-5419

Jeff Scafaria

Jeff Scafaria

Director Advisory, Strategy, KPMG US

+1 213-430-2174

KPMG is a proud sponsor of the 16th Annual Personalized Medicine Conference. We will have strategy thought leaders available to speak with conference attendees. In the complex and fast-moving Precision Medicines market, KPMG can provide deep scientific, technical, and business insights at a local and global level. The KPMG Precision Medicine strategy practice is a leader in this innovative area of medicine across all therapeutic areas, with all relevant stakeholders, and fueled by experience across the value chain.

We encourage you to read our latest case studies and thought leadership

   

Introduction to KPMG's Precision Medicine Practice
Our strategy practice is global, delivering solutions informed by our industry depth and local market knowledge.

  

Case study: Diagnostics client expands into biopharma services
Defining an organizational and capabilities roadmap for future market leadership for an oncology medical affairs team in a global biopharma client.
Case study: Biopharma client expands into precision medicine
Developing a diagnostics strategy to support EMEA launch and commercialization of a global biopharma’s targeted first-in-class oncology asset.


 

Case study: Driving supply chain resiliency for a CAR-T therapy manufacturer
The client, a CAR-T therapy manufacturer, identified the need to improve their cross-functional operating model to ensure sustainable supply and supply chain resiliency.
Case study: Global biopharma company identifies market positioning for their multiple myeloma therapy business
Conducting a detailed assessment of the current and future treatment paradigm in multiple myeloma for a leading biopharma client to assist with future market positioning.

  

Precision Medicine | Navigating innovation in the new normal
As the world emerges into a "new normal" across life sciences due to the COVID-19 pandemic, we are entering a new phase of Precision Medicine (PM). Whether you are a medical institution developing personalized and holistic services for your patients in all therapeutic areas, the field of Precision Medicine has changed for everyone.
“One-and-done” gene therapies
We are in a new era of scientific innovation where “one-and-done” gene therapies can potentially cure disease. However, headwinds still exist that will limit their use to rare and ultra-rare monogenic diseases for the next 5-10 years.

Related content


KPMG Healthcare & Life Sciences Institute

Register to receive timely insights

Register to receive timely insights

About Healthcare & Life Sciences at KPMG

Our practice

Learn more


Our capabilities

Learn more


Meet our team

Learn more